CA2369369A1 - Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins - Google Patents

Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins Download PDF

Info

Publication number
CA2369369A1
CA2369369A1 CA002369369A CA2369369A CA2369369A1 CA 2369369 A1 CA2369369 A1 CA 2369369A1 CA 002369369 A CA002369369 A CA 002369369A CA 2369369 A CA2369369 A CA 2369369A CA 2369369 A1 CA2369369 A1 CA 2369369A1
Authority
CA
Canada
Prior art keywords
alanine
serine
glycine
threonine
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369369A
Other languages
English (en)
French (fr)
Inventor
Gregory E. Garcia
Richard K. Gordon
Deborah R. Moorad
Bhupendra P. Doctor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research and Materiel Command USAMRMC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369369A1 publication Critical patent/CA2369369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002369369A 1999-05-14 2000-05-11 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins Abandoned CA2369369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13421699P 1999-05-14 1999-05-14
US60/134,216 1999-05-14
PCT/US2000/012909 WO2000069895A2 (en) 1999-05-14 2000-05-11 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins

Publications (1)

Publication Number Publication Date
CA2369369A1 true CA2369369A1 (en) 2000-11-23

Family

ID=22462297

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369369A Abandoned CA2369369A1 (en) 1999-05-14 2000-05-11 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins

Country Status (6)

Country Link
EP (1) EP1179022A2 (ja)
JP (1) JP2003502023A (ja)
AU (1) AU781608B2 (ja)
CA (1) CA2369369A1 (ja)
IL (1) IL146411A0 (ja)
WO (1) WO2000069895A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100195A (zh) * 2018-10-25 2020-05-05 安尼根有限公司 buforin衍生物及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
KR20020051124A (ko) * 2000-12-22 2002-06-28 이한웅 부포린 유도체를 포함하는 함암제
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP2134749B1 (en) 2007-03-22 2013-11-06 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
WO1998007440A1 (en) * 1996-08-24 1998-02-26 Samyang Genex Co., Ltd. A novel antimicrobial peptide isolated from bufo bufo gargarizans
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100195A (zh) * 2018-10-25 2020-05-05 安尼根有限公司 buforin衍生物及其用途
CN111100195B (zh) * 2018-10-25 2024-04-09 安尼根有限公司 buforin衍生物及其用途

Also Published As

Publication number Publication date
AU781608B2 (en) 2005-06-02
WO2000069895A2 (en) 2000-11-23
WO2000069895A3 (en) 2001-08-09
IL146411A0 (en) 2002-07-25
AU6197500A (en) 2000-12-05
EP1179022A2 (en) 2002-02-13
JP2003502023A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
US7375079B2 (en) Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins
Olivera et al. Purification and sequence of a presynaptic peptide toxin from Conus geographus venom
Sabatier et al. P05, a new leiurotoxin I-like scorpion toxin: Synthesis and structure-activity relationships of the. alpha.-amidated analog, a ligand of calcium-activated potassium channels with increased affinity
US6890537B2 (en) Antimicrobial theta defensins and methods of using same
US5464823A (en) Mammalian antibiotic peptides
Sabatier et al. Leiurotoxin I, a scorpion toxin specific for Ca2+‐activated K+ channels Structure‐activity analysis using synthetic analogs
US11965039B2 (en) Compstatin analogues and their medical uses
EP4272751A2 (en) Compstatin analogues and their medical uses
Habersetzer-Rochat et al. Structure-function relations of scorpion neurotoxins
AU781608B2 (en) Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
Lecomte et al. Chemical synthesis and structure–activity relationships of Ts κ, a novel scorpion toxin acting on apamin‐sensitive SK channel
US6713444B1 (en) Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
WO1998016549A1 (en) Antimicrobial peptide analogs of gramicidin s and compositions comprising them
Takagi et al. Aplysia myoglobins with an unusual amino acid sequence
US7235521B1 (en) Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins
WO2017115367A1 (en) Composition and method for treating amyotrophic lateral sclerosis
US6040293A (en) Clavanins
Biondi et al. Synthesis, conformation and biological activity of dermorphin and deltorphin I analogues containing N‐alkylglycine in place of residues in position 1, 3, 5 and 6
Lin et al. Chemical modification of cationic groups of a novel α-neurotoxin (Oh-4) from king cobra (Ophiophagus hannah) venom
MARILLER et al. Involvement of the N-terminal part of cyclophilin B in the interaction with specific Jurkat T-cell binding sites
CA2228730A1 (en) Styelins
KR20110068475A (ko) ４０２번 플로린 잔기가 수산화된 ＨＩＦ－１α 펩티드를 특이적으로 인식하는 단일클론항체 및 용도
JP2000095794A (ja) エンケファリン分解酵素の阻害剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued